Thyrocare Technologies Ltd.
Snapshot View

1310.05 -2.80 ▼-0.2%

23 July 2021, 04:00:00 P.M.
Volume: 4,504

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Compare with Industry peers
Website http://www.thyrocare.com
Financial Indicators
Market Cap 6,933.95 Cr.
Earnings per share (EPS) 21.40 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 61.28 Trailing Twelve Months Ending 2021-03
Industry PE 223.80 Trailing Twelve Months Ending 2021-03
Book Value / Share 80.26 Trailing Twelve Months Ending 2021-03
Price to Book Value 16.34 Calculated using Price: 1,311.40
Dividend Yield 1.91 Period Ending 2021-03
No. of Shares Subscribed 5.29 Cr. 52,874,419 Shares
FaceValue 10
Company Profile

Thyrocare Technologies Ltd. is India's first and most advanced Totally Automated Laboratory having its strong presence in several cities / towns in India and internationally. Thyrocare is India's first fully automated diagnostic laboratory with a focus on providing quality at affordable costs to laboratories and hospitals in India and other countries. Thyrocare operates with a Centralized Processing Laboratory (CPL) in Mumbai - India for esoteric tests; and Regional Processing Laboratory in major metro cities of India and other parts of Asia. It has focus on strong technologies, strong brands and strong systems that enable all laboratories to give their clients the best of science and technology at an affordable cost. Thyrocare became one of the first Indian diagnostic laboratories to obtain internationally renowned quality accreditations like ISO 9001-2000 rating as early as 2001, which is now escalated to ISO 9001:2008 and CAP (College of American Pathologists) certification in 2007.

Business area of the company

Thyrocare Technologies is an India-based healthcare service provider. The Company operates with a centralized processing laboratory (CPL) in Mumbai, India for esoteric tests, and regional processing laboratory in metro cities of India and other parts of Asia. The Company offers technologies, including Chemiluminescence Immunoassay (CLIA), Enzyme Linked Immunosorbent Assay (ELISA), High Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), Ion Selective Electrode (ISE), Fluorescence Flow Cytometry, Nephelometry, Photometry, Liquid Chromatography Mass Spectrometry (LC-MS), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Cytogenetics. The Company offers cancer diagnosis and water testing through its brands Nueclear and Whaters, respectively.

Major events and milestones

  • 2000: The company was incorporated in the name and style of ‘Thyrocare Technologies Limited’ and received a certificate for commencement of operations.
  • 2001: The company received ISO 9001 certification.
  • 2001: The company commenced commercial operations under the brand name ‘Thyrocare’ pursuant to the acquisition of business of TDPL and TBPL (which were incorporated in 1996).
  • 2005: The company received NABL accreditation.
  • 2006: The company issued certain fully convertible debentures aggregating to Rs 250 million to BCCL.
  • 2007: The company receives accreditation from the College of American Pathologists (CAP).
  • 2010: The company issued certain compulsorily convertible debentures aggregating to Rs 250 million to Agalia. Agalia also acquired certain Equity Shares aggregating to Rs 1,250 million from its Promoters and certain other persons.
  • 2010: The company launched wellness packages under the brand name ‘Aarogyam’.
  • 2011: The company migrated to ‘total laboratory automation system’ installed by Siemens for efficient handling of increasing volumes.
  • 2012: NVP acquired certain Equity Shares aggregating to Rs 1,200 million from certain entities.
  • 2013: EIF acquired certain Equity Shares from Agalia.
  • 2013: The company’s subsidiary commenced operations at the PET-CT centres at Navi Mumbai and conducted over 1,000 scans in the first year of operation.
  • 2014: The company had installed, India’s first and the world’s longest track automation system for seamless sample movements from Siemens Limited.
  • 2014: The company commissioned the operations in medical cyclotron facility in Navi Mumbai.
  • 2014: The company’s subsidiary commenced operations at the PET-CT centres in New Delhi and Hyderabad and the PET-CT centres at New Delhi conducted over 1,000 scans in the first year of operations.
  • 2015: The company opened RPLs in Delhi, Coimbatore, Hyderabad and Kolkata to expand its coverage and volume of tests and samples processed daily.
  • 2015: The company acquired the equipment for testing of water samples and commenced operating the equipment under the brand name ‘WHATERS’. These tests, at present, include physical and chemical testing, elements testing, microbiology testing, pesticide testing and volatile organic compounds testing.
  • 2015: The company’s subsidiary has completed over 10,000 scans at the PET-CT centres in New Delhi, over 10,000 scans at the PET-CT centres in Navi Mumbai from the date of inception and over 1,000 scans at the PET-CT centres in Hyderabad since inception.
  • 2015: The Company opened RPLs in Delhi, Coimbatore, Hyderabad and Kolkata to expand its coverage and volume of tests and samples processed daily.
  • 2015: The Company acquired the equipment for testing of water samples and commenced operating the equipment under the brand name ''WHATERS''. These tests, at present include physical and chemical testing, elements testing, microbiology testing, pesticide testing and volatile organic compounds testing.
  • 2015: The Subsidiary has completed over 10,000 scans at the PET-CT centres in New Delhi, over 10,000 scans at the PET-CT centres in Navi Mumbai from the date of inception and over 1,000 scans at the PET-CT centres in Hyderabad since inception.
  • 2016: Thyrocare Technologies are listed and admitted to dealings on the Exchange in the list of 'B' Group Securities.
  • 2016: Entered the Public listed sphere of healthcare – IPO.
  • 2016: Launched 2 new RPLs and NGSP Certification:- Certified with National Glycohemoglobin Standardization Program Certification (NGSP) for HbA1c Testing, and Launched 2 Regional Processing Laboratories- Bhopal and Bangalore, with state-of-the-art automations efficient as CPL, controlled via a centralized server.
  • 2016: Aarogyam Today:  Launched a second monthly publication addressing daily health concerns - Aarogyam Today.
  • 2016: Launched IFA (Immunofluorescence) for Autoimmunity testing.
  • 2017:  Launched Molecular Biology Division (PCR).
  • 2018: Patna Regional Processing Laboratory (RRL) was launched.
  • 2018: Last Mile Executive (LMEs) pickup service started in 15 plus cities.
  • 2018: Thyrocare and Thyroshop Mobile App were launched.
  • 2020: Thyrocare Technologies launching Blood-based Cancer Screening Profile.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-0.21%
1 Week
-0.83%
1 Month
-5.50%
3 Month
+28.78%
6 Month
+42.89%
1 Year
+116.66%
2 Year
+202.73%
5 Year
+131.72%
7 years 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 15.98 16.22 11.20 22.16 19.41 22.13 28.76
Return on Capital Employed (%) 24.57 25.66 21.05 33.93 31.36 35.14 38.52
Return on Assets (%) 13.41 14.09 10.20 20.59 17.93 18.73 22.44

Balance Sheet View Details

Particulars 7 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Shh. Funds 276 366 408 443 435 367 427
Non Curr. Liab. 9 10 9 10 14 21 18
Curr. Liab. 7 31 18 20 21 82 95
Minority Int. 36
Equity & Liab. 328 407 434 474 470 469 540
Non Curr. Assets 218 273 285 332 334 317 302
Curr. Assets 111 134 150 142 136 152 238
Misc. Exp. not W/O
Total Assets 328 407 434 474 470 469 540

Profit Loss View Details

Particulars 7 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Net Sales 183 241 304 356 403 434 495
Other Income 8 7 12 23 10 7 12
Total Income 191 248 317 380 413 441 507
Total Expenditure -110 -147 -189 -212 -249 -261 -323
PBIDT 81 101 128 168 164 180 184
Interest 0 -1 0 0 -1 -2 -1
Depreciation -13 -18 -18 -20 -26 -32 -30
Taxation -24 -30 -39 -52 -53 -52 -39
Exceptional Items -27 -2 -7
PAT 44 52 43 93 85 88 113

Cash Flow View Details

Particulars 7 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 34 68 90 107 100 168 116
Cash Fr. Inv. -18 -18 -42 -43 -12 1 -50
Cash Fr. Finan. -23 -45 -49 -64 -94 -165 -62
Net Change -6 5 0 0 -5 4 4
Cash & Cash Eqvt 5 10 10 10 5 9 13

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 65.95 66.06 66.01 66.01 66.04 66.11 66.14 66.14 66.14
Public 34.05 33.94 33.99 33.99 33.96 33.89 33.86 33.86 33.86
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Wed, 21 Jul 2021
Shareholding for the Period Ended June 30 2021
Thyrocare Technologies Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Fri, 16 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- RAMJEE DORAI
Designation :- Company Secretary and Compliance Officer
Sat, 03 Jul 2021
Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations 2015)
Thyrocare Technologies Ltd has informed BSE regarding the details of Voting results of AGM under Regulation 44(3) of SEBI (LODR) Regulations 2015. Kindly Click here

Technical Scans View Details

Fri, 23 Jul 2021
Strongly Outperforming Benchmark Index Strongly Outperforming Benchmark Index
Strongly Outperforming Sectoral Index Strongly Outperforming Sectoral Index
Close Within 2 Year High Zone Close Within 2 Year High Zone
Close Within 5 Year High Zone Close Within 5 Year High Zone
Both SRS And ARS Above Zero Both SRS And ARS Above Zero

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 694.00 +1.0%
Divi's Laboratories Ltd. 128,088.59 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,420.50 +0.7%
Cipla Ltd. 76,510.04 948.50 -0.1%
Cadila Healthcare Ltd. 62,965.29 615.05 -0.9%
Aurobindo Pharma Ltd. 56,484.48 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. 56,291.69 3,915.00 -1.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 31.81 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 3,915.00 -1.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 4.17 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 3,915.00 -1.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 0.18 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 10.09 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 12.53 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 3,915.00 -1.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 17,131.99 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 3,915.00 -1.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 1,546.98 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 3,915.00 -1.8%